Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 33 of 33 publications.

Razavi P, Ahmed M, Roush A, Parikh R, Hitchens A, Shen S, Safonov A, Jhaveri K, Robson M, Peacock N, Ma Y, Santarsiero E, Ganapathy V, Shah R, Amaefule A, Lteif A, Blakely J. Real-world (RW) risk of recurrence among patients (pts) diagnosed with stage II-III HR+/HER2− early breast cancer (EBC) treated with endocrine therapy (ET) in the US. J Clin Oncol. 2024 May;42(Suppl 16):e12533.

Moehler M, Xiao H, Blum SI, Elimova E, Cella D, Shitara K, Ajani JA, Janjigian YY, Garrido M, Shen L, Yamaguchi K, Liu T, Schenker M, Kowalyszyn R, Bragagnoli AC, Bruges R, Montesarchio V, Pazo-Cid R, Hunter S, Davenport E, Wang J, Kondo K, Li M, Wyrwicz L. Health-Related quality of life with nivolumab plus chemotherapy versus chemotherapy in patients with advanced gastric/gastroesophageal junction cancer or esophageal adenocarcinoma from CheckMate 649. J Clin Oncol. 2023 Dec 10;41(35):5388-99. doi: 10.1200/JCO.23.00170

Furqan M, Karanth S, Goyal RK, Shih Y, Cai B, Rombi J, Davis KL, Caro N, Saliba TR. Real-world assessment of treatment effectiveness in patients with advanced non-small cell lung cancer (aNSCLC) with MET exon 14 skipping (METex14). Poster presented at the 2023 ASCO Annual Meeting; June 2, 2023. Chicago, IL. [abstract] J Clin Oncol. 2023; 4((Suppl 16):e21112.

Paik PK, Goyal RK, Cai B, Price M, Davis K, Derrien Ansquer V, Caro N, Saliba TR. Real-world assessment of clinical outcomes in NSCLC patients with MET exon 14 skipping mutation and brain metastases (BM) treated with capmatinib. Poster presented at the ASCO 2022 Annual Meeting; June 2022. Chicago, IL. [abstract] J Clin Oncol. 2022 Jun 2; 40(16_suppl):e21171. doi: 10.1200/JCO.2022.40.16_suppl.e21171

Hamadani M, Graham C, Liao L, Zhang K, Strat HM, Ungar D, Ai W, Chen L, Carlo-Stella C. Long-term survival projections of loncastuximab tesirine-treated patients in relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). J Clin Oncol. 2022 Jun;40(16_suppl):e19551.

Ciruelos EM, Rugo HS, Mayer IA, Levy C, Forget F, Delgado Mingorance JI, Safra T, Masuda N, Park YH, Juric D, Conte P, Campone M, Loibl S, Iwata H, Zhou X, Park J, Ridolfi A, Lorenzo I, Andre F. Patient-reported outcomes in patients with PIK3CA-mutated hormone receptor-positive, human epidermal growth factor receptor 2–negative advanced breast cancer from SOLAR-1. J Clin Oncol. 2021 Jun 20;39(18):2005-15. doi: 10.1200/JCO.20.01139

Motzer RJ, Porta C, Alekseev B, Rha SY, Choueiri TK, Mendez-Vidal MJ, Hong SH, Kapoor A, Goh JC, Eto M, Wang J, Pan J, Ayele Asfaw A, He CS, Mody K, Cella D. Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC). Presented at the 2021 ASCO Conference; June 4, 2021. [abstract] J Clin Oncol. 2021; 39(Suppl 15):4502.

Wyrwicz L, Elimova E, Blum SI, Xiao H, Davenport E, Wang J, Hunter S, Li M, Kondo K, Mohler M. Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): interim results of nivolumab plus chemotherapy (N+C) versus (C) from CheckMate 649. Poster presented at the 2021 ASCO Conference; June 4, 2021. [abstract] J Clin Oncol. 2021; 39(Suppl 15):4066. doi: 10.1200/JCO.2021.39.15_suppl.4066

Cella D, Hackshaw MD, Vondeling GT, Bennett L, Garbinsky D, Saito K, Sugihara M, Bang YJ, Yamaguchi K, Shitara K. Quality-adjusted time without symptoms or toxicity (Q-TWiST) of trastuzumab deruxtecan (T-DXd) versus chemotherapy in patients with advanced gastric cancer from the DESTINY-Gastric01 trial. Poster presented at the 2021 ASCO Conference; June 4, 2021. [abstract] J Clin Oncol. 2021; 39(Suppl 15):4057. doi: 10.1200/JCO.2021.39.15_suppl.4057

Stirnadel-Farrant H, Mahajan A, Dhillon N, Patel N, Pokras S. Current treatment efficacy for metastatic soft tissue sarcoma: a targeted literature review. Poster presented at the 2020 ASCO Annual Meeting I; May 25, 2020. Chicago, IL. [abstract] J Clin Oncol. 2020 Jun; 38(15_Suppl). doi: 10.1200/JCO.2020.38.15_suppl.e23577

Poonnen P, Dong O, Winski D, Reed SD, Vashistha V, Bates JS, Kelley MJ, Voora D. Cost-effectiveness of genomic profiling in veterans with metastatic lung adenocarcinoma. Poster presented at the 2020 Virtual American Society of Clinical Oncology Scientific Program Meeting; May 29, 2020. [abstract] J Clin Oncol. 2020; 38(15 Suppl):7075.

Dzimitrowicz H, Esterberg L, Miles L, Zanotti G, Borham A, Harrison MR. Provider referral patterns following nephrectomy in high-risk locoregional renal cell carcinoma. Poster presented at the 2020 Genitourinary Cancers ASCO Symposium; February 15, 2020. San Francisco, CA. [abstract] J Clin Oncol. 2020; 38(Suppl 6):abstr 636.

Fizazi K, Shore ND, Tammela T, Kuss I, Le Berre M, Mohamed AF, Odom D, Bartsch J, Snapir A, Sarapohja T, Smith MR. Impact of darolutamide (DARO) on pain and quality of life (QoL) in patients (PTS) with nonmetastatic castrate-resistant prostate cancer (NMCRPC). Presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting; May 31, 2019. Chicago, IL. [abstract] J Clin Oncol. 2019 Jun; 37(15_Suppl).

Kummar S, Mascarenhas L, Geoerger B, Turpin B, Cox, MC, Yu S, Nanda S, Hiemeyer F, Keating KN, Chirila C, Gnanasakthy A, Davenport E, Hong DS, Drilon AE. Patient-reported outcomes from two global multicenter clinical trials of children and adults with tropomyosin receptor kinase (TRK) fusion cancer receiving larotrectinib. Poster presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting; June 1, 2019. Chicago, IL. [abstract] J Clin Oncol. 2019 Jun; 37(2019):6602.

Saif WM, Parikh R, Ray D, Kaye JA, Kurosky SK, Thomas K, Beveridge T, Mirakhur B, Lubeck CA, Nagar SP, Soares H. The sequencing of lanreotide (LAN) after octreotide LAR (OCT) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Poster presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting; June 1, 2018. Chicago, IL. [abstract] J Clin Oncol. 2018 Jun 1; 36(15_suppl):e16174. doi: 10.1200/JCO.2018.36.15_suppl.e16174

Winfree KB, Ainsworth C, Njue A, Molife C, Lyall M, Jen MH, Bittoni M, Heyes A, Carbone DP. Novel antiangiogenic drugs, immune checkpoint inhibitors, and chemotherapy in patients with aNSCLC who have aggressive disease: a systematic review. J Clin Oncol. 2018 May 16;36(15_suppl):e21120-e. doi: 10.1200/JCO.2018.36.15_suppl.e21120

Maiese E, Graham CN, Hawe E, Le Moine JG. Cost per median month of progression-free survival for daratumumab plus bortezomib and dexamethasone compared with carfilzomib plus dexamethasone in relapsed/refractory multiple myeloma. Poster presented at the 2018 ASCO Annual Meeting; June 1, 2018. Chicago, IL. [abstract] J Clin Oncol. 2018; p.e20037. doi: 10.1200/JCO.2018.36.15_suppl.e20037

Boye ME, Houghton K, Stull DE, Ainsworth C, Price GL. Estimating the effects of patient-reported outcome (PRO) diarrhea and pain measures on PRO fatigue: data analysis from a phase 2 study of abemaciclib monotherapy, a CDK4 and CDK6 inhibitor, in patients with HR+/HER2- breast cancer, after chemotherapy for metastatic disease: MONARCH 1. Poster presented at the 2017 ASCO Annual Meeting; June 4, 2017. Chicago, IL. [abstract] J Clin Oncol. 2017 Jun; 35(2017).

Maiese EM, Le Moine JG, Ainsworth C, Ahdesmaki O, Hawe E. Comparative efficacy of multiple myeloma therapies for treatment of first relapse: a systematic literature review and network meta-analysis. Poster presented at the 2017 ASCO Annual Meeting; June 5, 2017. Chicago, IL. [abstract] J Clin Oncol. 2017 Jun; 35(2017).

Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, Hainsworth JD, Maurer MJ, Cerhan JR, Link BK, Zelenetz AD, Friedberg JW. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National Lymphocare Study. J Clin Oncol. 2015 Aug 10;33(23):2516-22.

Tyczynski J, Williams S, Gregory N, Garratt M, Tchakov I, Davis KL, Kaye JA, Korsnes J, Lewis J. Real-world treatment patterns for platinum-sensitive recurrent serous ovarian cancer: findings from a multinational medical record review. Poster presented at the 2015 American Society of Clinical Oncology Annual Meeting; June 2015. Chicago, IL. [abstract] J Clin Oncol. 2015 Jun; 33(Suppl):e16548. doi: 10.1200/jco.2015.33.15_suppl.e16548

Chang J, Odom D, Radder C, Kappeler C, Xu R-h, Qin S, Kim TW, Li J. A post-hoc health-related quality of life analysis of patients with metastatic colorectal cancer in the phase III CONCUR trial. Poster presented at the ASCO Gastrointestinal Symposium 2015; May 2015. Chicago, IL. [abstract] J Clin Oncol. 2015 May; 33(Suppl 3):a667.

Goyal RK, Able SL, Davis KL, Brown J, Li L, Kaye JA. Real-world treatment patterns for advanced squamous non-small cell lung cancer in the U.S. Medicare population. Poster presented at the 2014 ASCO Annual Meeting; May 2014. Chicago, IL. [abstract] J Clin Oncol. 2014 Jun 11; 32(suppl):e17652.

Liepa AM, Candrilli SD, D'yachkova Y, Taipale K, Kaye JA. Economic burden of advanced hepatocellular carcinoma (HCC) in Spain among patients discontinuing first-line sorafenib. Poster presented at the 2014 Gastrointestinal Cancers Symposium; January 2014. [abstract] J Clin Oncol. 2014 Jan; 32(suppl 3):324. doi: 10.1200/jco.2014.32.3_suppl.324

Davis KL, Gutierrez B, Zyczynski TM, Kaye JA. Treatment patterns in men with castration-resistant prostate cancer receiving docetaxel. J Clin Oncol. 2012 May 20;30(Suppl 15):e15165. doi: 10.1200/jco.2012.30.15_suppl.e15165

Hale KS, Wang H, Karanth S, Raber MN, Carlson HR, Lenzi R, Abbruzzese JL, Mills GB, Varadhachary GR. Mutation profiling in patients with carcinoma of unknown primary using the Sequenom MassARRAY System. Poster presented at the 2012 ASCO Annual Meeting I; June 2012. [abstract] J Clin Oncol. 2012 May 20; 30(15):4131. doi: 10.1200/jco.2012.30.15_suppl.4131

Goyal RK, Meyer AM, Sheets NC, Federspiel JJ, Carpenter WR, Chen RC, Biddle AK. Cost-utility of proton therapy in the treatment of localized prostate cancer. Poster presented at the 2012 ASCO Annual Meeting I; June 2012. Chicago, IL. [abstract] J Clin Oncol. 2012 May 20; 30(15):e15184.

Bennett L, Zhao Z, Barber B, Zhou X, Peeters M, Zhang J, Xu F, Wiezorek J, Douillard JY. Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment. Poster presented at the American Society of Clinical Oncology Annual Meeting; June 2011. Chicago, IL. [abstract] J Clin Oncol. 2011 Nov 8; 29(15 Suppl):e19500. doi: 10.1038/bjc.2011.409.

Nooka AK, DeJoubner NJ, Nabhan C, Zhou X, Taylor M, Byrtek M, Miller TP, Friedberg JW, Zelenetz AD, Link BK, Cerhan JR, Dillon H, Levy D, Hirata J, Flowers C. Examination of the follicular lymphoma international prognostic index (FLIPI) in the national LymphoCare study (NLCS): a US patient cohort treated predominantly in community practices. Poster presented at the American Society of Clinical Oncology Annual Meeting; June 3, 2011. Chicago, IL. [abstract] J Clin Oncol. 2011 May 20; 29(15 Suppl):8036. doi: 10.1200/jco.2011.29.15_suppl.8036

Carlson HR, Karanth S, Zarzour MA, Lenzi R, Raber MN, Varadhachary GR. Patients with carcinoma of unknown primary with isolated carcinomatosis on presentation: clinicopathologic features and survival data. Poster presented at the 2011 ASCO Annual Meeting; June 2011. [abstract] J Clin Oncol. 2011 May 20; 29(Suppl 15):4123. doi: 10.1200/jco.2011.29.15_suppl.4123

Varadhachary GR, Edmonston TB, Karanth S, Carlson HR, Lebanony D, Rosenwald S, Lenzi R, Spector Y, Cohen D, Raber MN. Prospective gene signature study using microrna to predict the tissue of origin (ToO) in patients with cancer of unknown primary (CUP). Poster presented at the 2010 ASCO meeting; May 2010. [abstract] J Clin Oncol. 2010 May; 28(Suppl 15).

Wolowacz SE, Cameron DA, Tate HC, Bagust A. Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis. J Clin Oncol. 2008 Feb 20;26(6):925-33.

Smith T, Hillner B, Neighbors DM, McSorley P, LeChevalier T. An economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small cell lung cancer. J Clin Oncol. 1995;13(9):2166-73. doi: 10.1200/JCO.1995.13.9.2166.